keyword
MENU ▼
Read by QxMD icon Read
search

CMT1A neurotrophin-3

keyword
https://www.readbyqxmd.com/read/26764298/-therapy-for-charcot-marie-tooth-disease-from-the-standpoint-of-neurologists
#1
REVIEW
Masanori Nakagawa
To date, there is no approved pharmacologic treatment for any form of Charcot-Marie-Tooth disease (CMT). However, some clinical or preclinical trials for CMT1A have been undertaken, for example Neurotrophin-3, PXT3003, and neuregulin-1. Gene therapy for CMT1X, CMT2F and Giant axonal neuropathy using animal model or culture cells have been reported with some interesting results. Stem cell research for example iPS cells derived from patients with CMT2A or CMT2E, is being conducted to clarify the mechanism of CMT and find therapeutic clues...
January 2016: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/25842560/charcot-marie-tooth-type-1a-disease-from-patient-to-laboratory
#2
REVIEW
Shazia Perveen, Shazia Mannan, Abrar Hussain, Sumaira Kanwal
Charcot-Marie-Tooth (CMT) disease is a well-known neural or spinal type of muscular atrophy. It is the most familiar disease within a group of conditions called Hereditary Motor and Sensory Neuropathies (HMSN). The disease was discovered by three scientists several years ago. Several genes are involved as the causative agents for the disease. Hundreds of causative mutations have been found and research work for the identification of a novel locus and for the treatment of CMT1A is going on. This review article was planned to gather information on CMT disease and updates on its treatment...
February 2015: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/24162799/aav1-nt-3-gene-therapy-for-charcot-marie-tooth-neuropathy
#3
Zarife Sahenk, Gloria Galloway, Kelly Reed Clark, Vinod Malik, Louise R Rodino-Klapac, Brian K Kaspar, Lei Chen, Cilwyn Braganza, Chrystal Montgomery, Jerry R Mendell
Charcot-Marie-Tooth (CMT) neuropathies represent a heterogeneous group of peripheral nerve disorders affecting 1 in 2,500 persons. One variant, CMT1A, is a primary Schwann cell (SC) disorder, and represents the single most common variant. In previous studies, we showed that neurotrophin-3 (NT-3) improved the trembler(J) (Tr(J)) mouse and also showed efficacy in CMT1A patients. Long-term treatment with NT-3 was not possible related to its short half-life and lack of availability. This led to considerations of NT-3 gene therapy via adenoassociated virus (AAV) delivery to muscle, acting as secretory organ for widespread distribution of this neurotrophic agent...
March 2014: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/20553714/trkb-and-trkc-agonist-antibodies-improve-function-electrophysiologic-and-pathologic-features-in-trembler-j-mice
#4
Zarife Sahenk, Gloria Galloway, Chris Edwards, Vinod Malik, Brian K Kaspar, Amy Eagle, Brent Yetter, Alison Forgie, David Tsao, John C Lin
Neurotrophic factors have been considered as potential therapeutics for peripheral neuropathies. Previously, we showed that neurotrophin-3 (NT-3) promotes nerve regeneration in Trembler(J) (Tr(J)) mice and in sural nerves from patients with Charcot-Marie-Tooth 1A (CMT1A). The relatively short plasma half-life of NT-3 and other neurotrophins, however, pose a practical difficulty in their clinical application. Therapeutic agonist antibodies (AAb) targeting the neurotrophic receptors may circumvent this obstacle due to their high specificity and long half-life...
August 2010: Experimental Neurology
https://www.readbyqxmd.com/read/17628499/depleting-endogenous-neurotrophin-3-enhances-myelin-formation-in-the-trembler-j-mouse-a-model-of-a-peripheral-neuropathy
#5
Ning Liu, Sushama Varma, David Tsao, Eric M Shooter, Ravi J Tolwani
The heterozygous Trembler-J (TrJ/+) mouse, containing a point mutation in the peripheral myelin protein 22 (Pmp22) gene, is characterized by severe hypomyelination and is a representative model of Charcot-Marie-Tooth 1A (CMT1A) disease/Dejerine-Sottas syndrome (DSS). Given that the neurotrophin-3 (NT3)-TrkC signaling pathway is inhibitory to myelination during development, we investigated the role of the NT3-TrkC pathway in myelination and manipulated this pathway to improve myelin formation in the CMT1A/DSS mouse model...
October 2007: Journal of Neuroscience Research
https://www.readbyqxmd.com/read/16969156/animal-models-of-inherited-neuropathies
#6
REVIEW
Gerd Meyer Zu Hörste, Klaus-Armin Nave
PURPOSE OF REVIEW: Mutations in a number of genes have been associated with inherited neuropathies (Charcot-Marie-Tooth or CMT disease). This review highlights how animal models of demyelinating CMT have improved our understanding of disease mechanisms. Transgenic CMT models also allow therapies to be developed in a preclinical setting. RECENT FINDINGS: Rodent models for the most common subtypes of human CMT disease are now available, and two mouse mutants modeling the rare CMT4B subform have lately extended this repertoire...
October 2006: Current Opinion in Neurology
https://www.readbyqxmd.com/read/16157899/nt-3-promotes-nerve-regeneration-and-sensory-improvement-in-cmt1a-mouse-models-and-in-patients
#7
RANDOMIZED CONTROLLED TRIAL
Z Sahenk, H N Nagaraja, B S McCracken, W M King, M L Freimer, J M Cedarbaum, J R Mendell
BACKGROUND: Xenografts from patients with Charcot-Marie-Tooth type 1A (CMT1A) have shown delayed myelination and impaired regeneration of nude mice axons passing through the grafted segments. Neurotrophin-3 (NT-3), an important component of the Schwann cell (SC) autocrine survival loop, could correct these deficiencies. OBJECTIVE: To assess the efficacy of NT-3 treatment in preclinical studies using animal models of CMT1A and to conduct a double-blind, placebo-controlled, randomized, pilot clinical study to assess the efficacy of subcutaneously administered NT-3 in patients with CMT1A...
September 13, 2005: Neurology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"